• SINAT Proteins Regulate Autophagic Vesicle Degradation via V

  2026-06-29

  This study reveals that SINAT proteins control autophagic vesicle degradation in Arabidopsis by modulating the ubiquitination and proteolysis of the V-ATPase subunit VAB1. These findings clarify a key mechanism for vacuolar acidification and nutrient stress tolerance in plant autophagy, with implications for targeted manipulation of cellular degradation pathways.

• AI-Driven Discovery of Senolytics: Insights for Cancer Resea

  2026-06-28

  The referenced study demonstrates a machine learning approach to identify novel senolytic compounds by leveraging published, heterogeneous screening data. This enables efficient, cost-effective discovery of agents targeting senescent cells, with implications for cancer and age-related disease research.

• EZ Cap™ Firefly Luciferase mRNA (5-moUTP): Mechanism & Use

  2026-06-27

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) is a next-generation, in vitro transcribed mRNA for robust bioluminescent reporter assays. Its 5-moUTP modification and Cap 1 structure increase translation efficiency and reduce immune activation, ensuring high protein yield in gene regulation studies. This product is supplied by APExBIO and is optimized for stability, reproducibility, and compatibility with advanced mRNA delivery platforms.

• Targeting SARS-CoV-2 Nucleocapsid Phase Separation with GCG

  2026-06-26

  The referenced study reveals that SARS-CoV-2 nucleocapsid protein undergoes RNA-driven liquid–liquid phase separation (LLPS), a process essential for viral replication. It further demonstrates that (-)-gallocatechin gallate (GCG) disrupts this condensation, providing a mechanistic basis for novel antiviral strategies and guiding the development of molecular tools for phase separation research.

• Herbal Inhibition of Mast Cell–Mesothelial Crosstalk in Peri

  2026-06-26

  Chen et al. (2026) reveal that Astragalus membranaceus and Salvia miltiorrhiza (AS) disrupt mast cell–peritoneal mesothelial cell crosstalk by targeting the tryptase/PAR2/MAPK/NF-κB axis, thereby ameliorating peritoneal fibrosis in a mouse model. This work provides mechanistic insight into how traditional herbal agents may modulate immune-driven fibrotic responses during peritoneal dialysis.

• PD0325901 (SKU A3013): Reliable MEK Inhibition for Cancer Re

  2026-06-25

  This article addresses key challenges in cell viability and proliferation assays, highlighting how PD0325901 (SKU A3013) delivers reproducible MEK inhibition. Scenario-driven analysis guides biomedical researchers in optimizing protocols, interpreting data, and selecting reliable suppliers for advanced oncology workflows.

• Polybrene (Hexadimethrine Bromide) 10 mg/mL: Mechanism & Uti

  2026-06-25

  Polybrene (Hexadimethrine Bromide) is a validated viral gene transduction enhancer used to increase lentiviral and retroviral delivery efficiency. Its action is based on charge neutralization, facilitating viral attachment and uptake. APExBIO's product offers a sterile, stable formulation for reproducible results.

• Protease Inhibitor Cocktail: Optimizing Protein Integrity in

  2026-06-24

  The Protease Inhibitor Cocktail (100X in DMSO, EDTA plus) delivers robust, broad-spectrum protein degradation prevention across Western blot, Co-IP, and advanced kinase workflows. Leveraging insights from HSP90-METTL3 axis disruption in colorectal cancer, this guide details protocol enhancements and troubleshooting strategies that maximize assay fidelity.

• Cardamomin Mitigates Oxidative Damage in Ischemic Stroke Mod

  2026-06-23

  This study elucidates the neuroprotective action of cardamomin, a chalcone from Amomum villosum, against oxidative stress and ischemic injury in both cellular and rat models. It details mechanistic insights involving NRF2 activation and cell death pathway regulation, providing a refined framework for evaluating antioxidant interventions in cerebral ischemic stroke.

• Probenecid: Applied Workflows for Tumor Resistance and Neuro

  2026-06-23

  Probenecid (4-(dipropylsulfamoyl)benzoic acid) stands out as a dual-purpose reagent for overcoming multidrug resistance in tumor models and conferring neuroprotection in cerebral ischemia/reperfusion injury. This guide delivers protocol refinements, troubleshooting strategies, and actionable insights to maximize research impact with Probenecid from APExBIO.

• Mavorixafor Phase 3 Trial: Precision Therapy Advances in WHI

  2026-06-22

  The phase 3 study by Badolato et al. demonstrates that mavorixafor, an oral CXCR4 antagonist, significantly increases neutrophil and lymphocyte counts while reducing infection rates in patients with WHIM syndrome. This represents a pivotal advance in precision immunotherapy for rare inherited neutropenias and highlights the importance of targeted intervention in treating complex immunodeficiencies.

• Difloxacin HCl: Mechanism, Benchmarks, and Research Use Case

  2026-06-22

  Difloxacin HCl, a quinolone antimicrobial antibiotic, inhibits bacterial DNA replication and demonstrates capacity to reverse multidrug resistance in cell models. This article details its mechanism, protocol parameters, and limitations based on peer-reviewed and vendor-curated evidence.

• Sunitinib: Multi-Targeted RTK Inhibitor for Advanced Cancer

  2026-06-21

  Sunitinib’s nanomolar RTK inhibition unlocks new avenues in cancer models, especially those with complex angiogenesis or cell cycle dysregulation. This article delivers actionable workflows, evidence-backed troubleshooting, and key experimental insights to help researchers harness Sunitinib’s full potential in translational oncology.

• Cabazitaxel (XRP6258): Practical Parameters for Resistant Tu

  2026-06-20

  Cabazitaxel addresses the challenge of taxane resistance in cancer research, providing an effective tool for disrupting microtubule dynamics in P-glycoprotein-expressing tumor models. It is best suited for DMSO- or ethanol-based in vitro and in vivo assays, and is not recommended for water-based systems or long-term solution storage.

• miR-196a Drives Esophageal Cancer Aggressiveness via MYC/TER

  2026-06-19

  This study identifies microRNA-196a as a critical driver of esophageal adenocarcinoma (EAC) aggressiveness through coordinated activation of the MYC/TERT/NFκB axis. The work elucidates how miR-196a promotes epithelial-to-mesenchymal transition, cell motility, and oncogenic signaling, providing mechanistic insight and potential intervention points for cancer research.

450 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page